checkAd
    Startseite > Aktien > Pasithea Therapeutics > Nachrichten
    Pasithea Therapeutics Aktie
    6,5000
     
    USD
    -1,81 %
    -0,1200 USD
    Letzter Kurs 02:00:00 Nasdaq
    6,5000
     
    USD
    100 STK
    Geldkurs 21.05.24
    6,5900
     
    USD
    100 STK
    Briefkurs 21.05.24
    ISIN: US70261F2020 · SYM: KTTA · USA

    Neueste Nachrichten

    Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
    08.01.24 · globenewswire · Pasithea Therapeutics
    Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
    02.01.24 · globenewswire · Pasithea Therapeutics
    Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
    28.12.23 · globenewswire · Pasithea Therapeutics
    Pasithea Therapeutics Announces Results from 2023 Annual Meeting
    19.12.23 · globenewswire · Pasithea Therapeutics
    Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
    29.11.23 · globenewswire · Pasithea Therapeutics
    Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
    29.11.23 · globenewswire · Pasithea Therapeutics
    Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
    09.11.23 · globenewswire · Pasithea Therapeutics
    Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
    14.09.23 · globenewswire · Pasithea Therapeutics
    Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
    07.09.23 · globenewswire · Pasithea Therapeutics
    Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv
    01.08.23 · globenewswire · Pasithea Therapeutics
    Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash
    20.07.23 · globenewswire · Pasithea Therapeutics
    Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.
    20.07.23 · globenewswire · Pasithea Therapeutics